Table 2.

List of some FLT3 inhibitors.
 IC50 refers to the concentration required for the inhibition of FLT3 autophosphorylation. “Other receptors” refers to other receptors known to be inhibited by the compound with an IC50 similar to that for FLT3.

CompoundChemical ClassFLT3 IC50Other receptorsClinical Trial
AG1295 Quinoxaline 300 nM PDGFR, KIT  
AG1296 Quinoxaline 300 nM PDGFR, KIT  
AGL2043 Quinoxaline 100 nM PDGFR, KIT  
D64406 Bis-indlyl- methanone 300 nM PDGFR, KIT  
SU5416 3-Substituted indolinone 100 nM KIT, VEGFR Phase I 
SU5614 3-Substituted indolinone 10 nM KIT, FMS  
SU11248 3-Substituted indolinoneindolinone 50 nM KIT, PDGFR, VEGFR Phase I 
MLN518 Quinazoline 30 nM KIT, PDGFR, Phase II 
CEP-701 Indolocarbazole 2 nM TRKA Phase III 
PKC412 Indolocarbazole 10 nM KIT Phase III planned 
GTP-14564 Cyclopenta-[a]- inden 300 nM KIT, FMS, PDGFR  
Ki23819 Quinoline-urea 1 nM NR  
CHIR-258 Benzimidalzole- quinoline 10 nM KIT, FMS, FGFR, VEGFR Phase 1 
KW-2449 NR 6 nM FLT3, KIT, Aurora Phase 1 planned 
CompoundChemical ClassFLT3 IC50Other receptorsClinical Trial
AG1295 Quinoxaline 300 nM PDGFR, KIT  
AG1296 Quinoxaline 300 nM PDGFR, KIT  
AGL2043 Quinoxaline 100 nM PDGFR, KIT  
D64406 Bis-indlyl- methanone 300 nM PDGFR, KIT  
SU5416 3-Substituted indolinone 100 nM KIT, VEGFR Phase I 
SU5614 3-Substituted indolinone 10 nM KIT, FMS  
SU11248 3-Substituted indolinoneindolinone 50 nM KIT, PDGFR, VEGFR Phase I 
MLN518 Quinazoline 30 nM KIT, PDGFR, Phase II 
CEP-701 Indolocarbazole 2 nM TRKA Phase III 
PKC412 Indolocarbazole 10 nM KIT Phase III planned 
GTP-14564 Cyclopenta-[a]- inden 300 nM KIT, FMS, PDGFR  
Ki23819 Quinoline-urea 1 nM NR  
CHIR-258 Benzimidalzole- quinoline 10 nM KIT, FMS, FGFR, VEGFR Phase 1 
KW-2449 NR 6 nM FLT3, KIT, Aurora Phase 1 planned 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal